Kaye Biotech Inc. had the following equity account balances at December $31,2022$ :

Preferred shares, $$2\mathrm{.}85,$ non$-$cumulative,

Authorized: $21,600$ shares

Issued and outstanding: $5,800$ shares

$$40,600$

Common shares,

Authorized: Unlimited

Issued and outstanding: $89,000$ shares

$301,234$

Retained earnings

$43,800$

On February $1,2023,5,800$ preferred shares were issued at $$8\mathrm{.}50$ each. The board of directors declared and paid the annual cash dividend on the preferred shares on June $30,2023,$ and a $11\%$ common share dividend was declared and distributed on the same day when the market price per common share was $$4\mathrm{.}60.$ On October $1,2023,21,600$ common shares were issued at $$4\mathrm{.}74$ each. Profit earned during $2023$ was $$416,800.$

Required:

Using the information provided, prepare the statement of changes in equity for the year ended December $31,2023.($Amounts to be deducted should be indicated by a minus sign.$)$

KAYE BIOTECH INC.

Statement of Changes in Equity

For Year Fnded Decemher $31,2023$